Latest News From Lumira Ventures

Forbius’ AVID200 IND Receives Clearance from the FDA to Start Phase 1 Scleroderma Clinical Trial

Ahmed Khan Forbius (Formation Biologics), Portfolio News

Forbius announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for AVID200, an isoform-selective TGF-β inhibitor. This enables the company to begin a Phase 1 clinical study to evaluate AVID200 as a potential treatment for diffuse cutaneous systemic …